Sorafenib Modulates the LPS- and Aβ-Induced Neuroinflammatory Response in Cells, Wild-Type Mice, and 5xFAD Mice

Ji‐Eun Kim, Jin-Hee Park, Seon Kyeong Park, Hyang‐Sook HoeFrontiers in Immunology 2021 · DOI

TL;DR

This study investigates the potential of sorafenib, an existing cancer drug, to combat neuroinflammation. Researchers found that sorafenib effectively reduces key inflammatory markers in both cell cultures and animal models, suggesting it could be a promising therapeutic agent for neuroinflammatory diseases.

What Problem Does This Paper Address?

Neuroinflammation, an immune response in the central nervous system (CNS), is a double-edged sword. While it's crucial for responding to injury and infection, chronic or dysregulated neuroinflammation contributes to various neurological disorders, including Alzheimer's disease. Current treatments for neuroinflammation are limited, highlighting the need for new therapeutic strategies. This paper explores whether sorafenib, a multi-kinase inhibitor already approved for cancer treatment, can modulate and suppress neuroinflammatory responses.

Methods

The researchers employed a multi-pronged approach:

  • In vitro studies: They used BV2 microglial cells and primary rat astrocytes to assess sorafenib's effects on inflammatory responses. Techniques included:
  • MTT assay: To determine sorafenib's cytotoxicity and establish safe working concentrations.
  • Reverse Transcription PCR (RT-PCR) and Real-Time PCR: To measure the mRNA levels of key proinflammatory cytokines like COX-2, IL-1β, IL-6, and iNOS.
  • Western Blotting (WB): To analyze the phosphorylation status of signaling proteins such as AKT and p38, which are involved in inflammatory pathways.
  • Immunocytochemistry (ICC): To visualize the localization and activation of transcription factors like p-STAT3 and p-NF-κB within the cells.
  • In vivo studies: They used wild-type mice and 5xFAD mice (a model for Alzheimer's disease) to evaluate sorafenib's effects in a living organism. Techniques included:
  • Intraperitoneal (i.p.) administration: Sorafenib was administered to mice.
  • Lipopolysaccharide (LPS) injection: LPS, a potent inducer of neuroinflammation, was used to trigger inflammatory responses in wild-type mice.
  • Immunofluorescence Staining (IF): Brain sections were analyzed to detect and quantify markers of microglial activation (Iba-1), astrogliosis (GFAP), and inflammatory mediators (COX-2), as well as phosphorylated signaling proteins (p-AKT, p-STAT3).
  • Alzheimer's disease model (5xFAD mice): These mice were used to assess sorafenib's impact on amyloid-beta (Aβ)-induced neuroinflammation.

Datasets

Not discussed in the paper.

Key Insights and Ideas

  • Sorafenib's dual role in neuroinflammation: The study reveals that sorafenib can both prevent and treat LPS-induced neuroinflammation, acting as a modulator rather than just a blocker.
  • Cell-specific effects: Sorafenib's impact on inflammatory cytokine production varies between microglia and astrocytes, suggesting a nuanced mechanism of action. It significantly reduced COX-2 and IL-1β in microglia but primarily affected COX-2 in astrocytes.
  • Targeting key signaling pathways: Sorafenib appears to exert its effects by modulating crucial signaling cascades like AKT/p38 and STAT3/NF-κB, which are central to inflammatory responses.
  • Translational potential: The fact that sorafenib is already an FDA-approved drug makes its potential therapeutic application for neuroinflammatory conditions more readily achievable.
  • Differential effects in AD models: While sorafenib effectively reduced astrogliosis in the 5xFAD mouse model, it did not significantly impact microgliosis, suggesting specific targets within the Alzheimer's pathology.

Key Results

  • In vitro: Sorafenib (at 5 µM) reduced LPS-induced COX-2 and IL-1β mRNA levels in BV2 microglial cells, and COX-2 mRNA in primary astrocytes. It also suppressed LPS-induced phosphorylation of AKT and p38, and nuclear translocation of p-STAT3 and p-NF-κB in microglia.
  • In wild-type mice: Pretreatment with sorafenib significantly decreased LPS-induced microgliosis (Iba-1) and astrogliosis (GFAP), as well as COX-2 levels in the brain. It also reduced AKT phosphorylation. Post-treatment with sorafenib also showed similar inhibitory effects on microgliosis and astrogliosis.
  • In 5xFAD mice: Daily sorafenib treatment for 3 days significantly reduced Aβ-induced astrogliosis (GFAP) but did not significantly alter microgliosis (Iba-1).

Limitations and Future Work

  • Duration and dose of sorafenib: The study used a 3-day treatment regimen for sorafenib in mice. The authors suggest that longer treatment periods and/or higher doses might be necessary to observe more pronounced effects, particularly on microgliosis in the 5xFAD model.
  • Mechanism of action in astrocytes: While sorafenib affected COX-2 in astrocytes, its impact on other inflammatory cytokines was limited. Further research is needed to fully elucidate its role in astrocyte-mediated neuroinflammation.
  • Synaptic function: The study briefly explored sorafenib's effects on synaptic proteins, showing a reversal of LPS-induced changes in shank-1. However, the authors suggest more comprehensive future work to assess its impact on synaptic and cognitive function.
  • Specific kinase targets: The authors plan to investigate whether sorafenib's effects on neuroinflammation are mediated by its inhibition of Raf-1, VEGFR2, PDGFRẞ, or a combination thereof.
  • Broader therapeutic potential: Future studies will explore sorafenib's efficacy in non-LPS models of neuroinflammation and its potential for treating conditions beyond acute inflammatory responses.

Summary updated

Abstract

Sorafenib is FDA-approved for the treatment of primary kidney or liver cancer, but its ability to inhibit many types of kinases suggests it may have potential for treating other diseases. Here, the effects of sorafenib on neuroinflammatory responses in vitro and in vivo and the underlying mechanisms were assessed. Sorafenib reduced the induction of mRNA levels of the proinflammatory cytokines COX-2 and IL-1β by LPS in BV2 microglial cells, but in primary astrocytes, only COX-2 mRNA levels were altered by sorafenib. Interestingly, sorafenib altered the LPS-mediated neuroinflammatory response in BV2 microglial cells by modulating AKT/P38-linked STAT3/NF-kB signaling pathways. In LPS-stimulated wild-type mice, sorafenib administration suppressed microglial/astroglial kinetics and morphological changes and COX-2 mRNA levels by decreasing AKT phosphorylation in the brain. In 5xFAD mice (an Alzheimer’s disease model), sorafenib treatment daily for 3 days significantly reduced astrogliosis but not microgliosis. Thus, sorafenib may have therapeutic potential for suppressing neuroinflammatory responses in the brain.
BibTeX
@inproceedings{kim2021sorafenib,
  author = {Ji‐Eun Kim and Jin-Hee Park and Seon Kyeong Park and Hyang‐Sook Hoe},
  title = {{Sorafenib Modulates the LPS- and Aβ-Induced Neuroinflammatory Response in Cells, Wild-Type Mice, and 5xFAD Mice}},
  booktitle = {Frontiers in Immunology},
  year = {2021},
  doi = {10.3389/fimmu.2021.684344},
}
Figure